Abstract
Traditional treatment for juvenile rheumatoid arthritis (JRA) includes the use of NSAIDs, corticosteroids, and DMARDs such as methotrexate; however, these drugs are not effective in all patients. Although the use of tumor necrosis factor inhibitors has dramatically improved outcomes in patients with JRA, the long-term safety of these agents in children remains a concern. Lovell et al. recently reported the long-term follow-up of a randomized controlled trial that had shown in 69 patients that etanercept was effective in the treatment of JRA. In the 8-year, open-label extension study (n = 58), the drug remained well tolerated and few adverse events were reported. These results indicate that a substantial number of patients with JRA will have a sustained response to etanercept and that the drug can be given safely for at least 8 years. Although the patients in this study were diagnosed with polyarticular JRA according to American College of Rheumatology criteria, it is reasonable to generalize the findings to patients with polyarticular juvenile idiopathic arthritis as defined by the International League of Associations for Rheumatology guidelines.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hashkes PJ and Laxer RM (2005) Medical treatment of juvenile idiopathic arthritis. JAMA 294: 1671–1684
Ilowite NT (2002) Current treatment of juvenile rheumatoid arthritis. Pediatrics 109: 109–115
Lovell DJ et al. for the Pediatric Rheumatology Collaborative Study Group (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342: 763–769.
Wallace CA et al. (2005) Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 52: 3554–3562
Lovell et al. (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58: 1496–1504
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Hirsch, R. Is long-term etanercept therapy safe and effective in patients with juvenile RA?. Nat Rev Rheumatol 4, 628–629 (2008). https://doi.org/10.1038/ncprheum0925
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0925